casegugl.blogg.se - Humalog copay card

Patients using insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure. Hyperglycemia and Ketoacidosis Due to Insulin Pump Device Malfunction: Malfunction of the insulin pump or insulin infusion set or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis.If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered. Patients should be observed for signs and symptoms of heart failure. Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists: Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including NovoLog ®.Monitor potassium levels in patients at risk for hypokalemia if indicated (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentration).

Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death.

Hypokalemia: All insulins, including NovoLog ®, can cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia.

Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog ®.

Hypoglycemia Due to Medication Errors: To avoid medication errors and accidental mix-ups between NovoLog ® and other insulin products, instruct patients to always check the insulin label before injection.

Patients and caregivers must be educated to recognize and manage hypoglycemia. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia. Other factors which may increase the risk of hypoglycemia include changes in meal pattern, changes in level of physical activity, or changes to co-administered medication. As with all insulins, the glucose lowering effect time course of NovoLog ® may vary in different individuals or at different times in the same individual and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature.

Risk Factors for Hypoglycemia: The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal.

Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers), or in patients who experience recurrent hypoglycemia. Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual. Hypoglycemia can impair concentration ability and reaction time this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Severe hypoglycemia can cause seizures, may lead to unconsciousness, may be life threatening or cause death.

Hypoglycemia: Hypoglycemia is the most common adverse effect of all insulins, including NovoLog ®.

Adjustments in concomitant anti-diabetic treatment may be needed. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia.Sharing poses a risk for transmission of blood-borne pathogens. Patients using NovoLog ® vials must never share needles or syringes with another person. Never Share a NovoLog ® FlexPen, NovoLog ® FlexTouch, PenFill ® Cartridge, or PenFill ® Cartridge Device Between Patients, even if the needle is changed.